Biotech Division of Greenland Mines Announces Australian Patent Grant for Klotho Gene Therapy Technology for Treatment of Neuromuscular Diseases
Rhea-AI Summary
Greenland Mines (Nasdaq: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 for Klotho gene therapy technology exclusively licensed by its Biotech Division. The patent covers human gene therapy using a muscle-cell specific promoter linked to a gene encoding human Klotho s-KL protein to treat motor impairment.
The claims extend to neuronal cells, induced pluripotent stem cells, and delivery systems including adeno-associated viral and non-viral vectors with muscle or motor neuron tropism. According to Greenland Mines, this grant expands its global intellectual property protecting the Klotho-based platform and supports advancement of KLTO-202 toward clinical development in neuromuscular diseases.
Positive
- Australian patent granted for Klotho neuromuscular gene therapy technology (No. 2023252508)
- Exclusive license to patented Klotho platform for the company’s Biotech Division
- Broad IP scope covering neuronal cells, iPSCs, AAV and non-viral delivery vectors
- Supports KLTO-202 program as it progresses toward planned clinical development
Negative
- None.
News Market Reaction – GRML
In the Jul 10 session, GRML gained 1.24%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Field campaign staffing | Positive | -4.2% | Added leading magmatic researchers to 2026 Skaergaard field campaign team. |
| Jun 25 | Technical workshop | Positive | -8.0% | Concluded workshop defining next phase of Skaergaard project development. |
| Jun 22 | Drilling contract | Positive | -8.6% | Signed 7,500-meter diamond drilling contract for 2026 Skaergaard program. |
| Jun 18 | Resource estimate program | Positive | -3.1% | Engaged firms to deliver S-K 1300 resource estimate for Sarfartoq project. |
| Jun 16 | Strategic investment | Positive | +12.2% | Entered share exchange to gain up to 19.9% stake in AnorTech. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often seen the stock move counter to generally positive operational and strategic announcements.
Key Terms
muscle-cell specific promoter medical
induced pluripotent stem cells medical
adeno-associated viral vectors medical
non-viral vectors medical
motor neuron diseases medical
neuromuscular diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- via IBN -- Greenland Mines Ltd (Nasdaq: GRML) ("Greenland Mines" or the "Company") today announced that IP Australia has granted Australian Patent No. 2023252508, entitled "Treatment of Neuromuscular Diseases via Gene Therapy that Expresses Klotho Protein," covering technology exclusively licensed by the Company's Biotech Division. The patented technology was invented by researchers at Universitat Autònoma de Barcelona and collaborating institutions.
The issued patent protects the use of a human gene therapy using a muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding the human Klotho s-KL protein for treating motor impairment. The patent includes claims covering neuronal cells and induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence, as well as other cellular delivery systems such as adeno-associated viral vectors (AAV) and non-viral vectors with muscle-cell and/or motor neuron-cell tropism.
The patent further expands the Company's growing global intellectual property estate supporting its Klotho-based therapeutic platform.
Dr. Joseph Sinkule, the Company’s founder and CEO, stated: "Over the past three years, we have advanced KLTO-202 around a simple but compelling scientific premise—that restoring or supplementing human Klotho expression may help address the underlying biology of ALS and other debilitating neuromuscular diseases. A growing body of research has demonstrated the critical role Klotho plays in neuronal health, muscle function, aging, and cellular resilience. This patent strengthens the intellectual property protecting our approach, reinforces the long-term value of our biotechnology platform, and provides an important foundation as we continue advancing KLTO-202 toward clinical development. We believe Klotho has the potential to represent an entirely new therapeutic paradigm for treating motor neuron diseases."
Neuromuscular diseases include ALS, spinal muscular atrophy (SMA), Charcot-Marie-Tooth disease, multiple sclerosis, muscular dystrophies, peripheral neuropathies, traumatic nerve injury, age-related muscular atrophy, and numerous other neuromuscular and motor neuron disorders.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho's KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and select midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
Forward‑Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website:
www.greenlandmines.com
